BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huitema MP, Grutters JC, Rensing BJWM, Reesink HJ, Post MC. Pulmonary hypertension complicating pulmonary sarcoidosis. Neth Heart J 2016;24:390-9. [PMID: 27194118 DOI: 10.1007/s12471-016-0847-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Kouranos V, O'hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Nathan SD. Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. Respiratory Medicine 2018;139:72-8. [DOI: 10.1016/j.rmed.2018.04.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
2 daSilva-deAbreu A, Mandras SA. Sarcoidosis-Associated Pulmonary Hypertension: An Updated Review and Discussion of the Clinical Conundrum. Curr Probl Cardiol 2021;46:100506. [PMID: 31889552 DOI: 10.1016/j.cpcardiol.2019.100506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Narechania S, Renapurkar R, Heresi GA. Mimickers of chronic thromboembolic pulmonary hypertension on imaging tests: a review. Pulm Circ 2020;10:2045894019882620. [PMID: 32257112 DOI: 10.1177/2045894019882620] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
4 Tiosano S, Versini M, Dar Antaki L, Spitzer L, Yavne Y, Watad A, Gendelman O, Comaneshter D, Cohen AD, Amital H. The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension – A cohort study. Clinical Immunology 2019;199:57-61. [DOI: 10.1016/j.clim.2018.12.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
5 Jose A, Delio J, Gwizdala J, Goulart H, Ahari JE. Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2018;35:308-16. [PMID: 32476918 DOI: 10.36141/svdld.v35i4.6855] [Reference Citation Analysis]
6 Huitema MP, Bakker ALM, Mager JJ, Snijder RJ, Rensing BJWM, Swaans MJ, Grutters JC, Post MC. Predicting pulmonary hypertension in sarcoidosis; value of PH probability on echocardiography. Int J Cardiovasc Imaging 2020;36:1497-505. [DOI: 10.1007/s10554-020-01859-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sascău R, Anghel L, Clement A, Bostan M, Radu R, Stătescu C. The Importance of Multimodality Imaging in the Diagnosis and Management of Patients with Infiltrative Cardiomyopathies: An Update. Diagnostics (Basel) 2021;11:256. [PMID: 33562254 DOI: 10.3390/diagnostics11020256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Baughman RP, Shlobin OA. Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far. Eur Respir J 2017;50:1701725. [PMID: 29051277 DOI: 10.1183/13993003.01725-2017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
9 Elwazir MY, Bois JP, Abou Ezzeddine OF, Chareonthaitawee P. Imaging and Quantification of Cardiac Sarcoidosis. Semin Nucl Med 2020;50:283-94. [PMID: 32540026 DOI: 10.1053/j.semnuclmed.2020.03.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Currie BM, Davies EW, Beaudet A, Stassek L, Kleinman L, Baughman RP. Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT™) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): a qualitative interview study. BMC Pulm Med 2021;21:365. [PMID: 34772372 DOI: 10.1186/s12890-021-01694-1] [Reference Citation Analysis]
11 Post MC, van der Wall EE. Pulmonary hypertension: the importance of a multidisciplinary approach. Neth Heart J 2016;24:369-71. [PMID: 27189215 DOI: 10.1007/s12471-016-0848-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Patel M, Ladak K. Author Response: Pulmonary Vasodilators in Sarcoidosis-associated Pulmonary Hypertension. Clin Med Res 2020;18:55-7. [PMID: 32816988 DOI: 10.3121/cmr.2020.1600] [Reference Citation Analysis]
13 Prasad JD. Screening for pulmonary hypertension in interstitial lung disease: Many reasons to ECHO!: Editorial. Respirology 2018;23:646-7. [DOI: 10.1111/resp.13263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Kurmann R, Mankad SV, Mankad R. Echocardiography in Sarcoidosis. Curr Cardiol Rep 2018;20:118. [PMID: 30259211 DOI: 10.1007/s11886-018-1065-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
15 daSilva-deAbreu A, Bracamonte-Baran W, Condado JF, Babaliaros V, Tafur-Soto J, Mandras SA. Characteristics and Outcomes of Pulmonary Angioplasty With or Without Stenting for Sarcoidosis-Associated Pulmonary Hypertension: Systematic Review and Individual Participant Data Meta-Analysis. Curr Probl Cardiol 2021;46:100616. [PMID: 32532452 DOI: 10.1016/j.cpcardiol.2020.100616] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Ho JQ, Kuschner WG. Management of Sarcoidosis-associated Pulmonary Hypertension. Clin Med Res 2020;18:55. [PMID: 32571775 DOI: 10.3121/cmr.2020.1556] [Reference Citation Analysis]
17 Savale L, Huitema M, Shlobin O, Kouranos V, Nathan SD, Nunes H, Gupta R, Grutters JC, Culver DA, Post MC, Ouellette D, Lower EE, Al-Hakim T, Wells AU, Humbert M, Baughman RP. WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. Eur Respir Rev 2022;31:210165. [PMID: 35140103 DOI: 10.1183/16000617.0165-2021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Bazmpani MA, Arsos G, Zarogoulidis P, Doumas A, Dimitroulas T, Sianos G, Hadjimiltiades S, Kouskouras K, Mayer E, Karvounis H, Giannakoulas G. A case of sarcoidosis-associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension. Pulm Circ 2018;8:2045894018768289. [PMID: 29537341 DOI: 10.1177/2045894018768289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Saketkoo LA, Russell AM, Jensen K, Mandizha J, Tavee J, Newton J, Rivera F, Howie M, Reese R, Goodman M, Hart P, Strookappe B, De Vries J, Rosenbach M, Scholand MB, Lammi MR, Elfferich M, Lower E, Baughman RP, Sweiss N, Judson MA, Drent M. Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. Diagnostics (Basel) 2021;11:1089. [PMID: 34203584 DOI: 10.3390/diagnostics11061089] [Reference Citation Analysis]
20 Kirkil G, Lower E, Baughman R. Advances in predicting patient survival in pulmonary sarcoidosis. Expert Opinion on Orphan Drugs 2021;9:113-22. [DOI: 10.1080/21678707.2021.1925107] [Reference Citation Analysis]
21 Vis D, Boucly A, Humbert M, Weatherald J. Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension? Eur Respir J 2020;55:2000700. [PMID: 32409427 DOI: 10.1183/13993003.00700-2020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Mathijssen H, Huitema MP, Bakker ALM, Smits F, Mager JJ, Snijder RJ, Grutters JC, Post MC. Clinical Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension. Heart Lung Circ 2021;30:1502-8. [PMID: 33933365 DOI: 10.1016/j.hlc.2021.03.279] [Reference Citation Analysis]